Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NephroFortis
- Development stage
- Preclinical
- Lead developer
- TRIZ Biopharma International
- Modality
- Small Molecules
01
Overview
NephroFortis is a preclinical-stage small molecule nephroprotector being developed by TRIZ Biopharma International. It is specifically designed to prevent drug-induced nephrotoxicity and acute kidney injury (AKI), particularly damage caused by polymyxin antibiotics. The drug's mechanism of action involves binding to the megalin receptor (LRP2) in kidney proximal tubule cells with a higher affinity than nephrotoxic agents like polymyxins. By competitively binding to this receptor, NephroFortis blocks the uptake of these toxins into the kidney cells, thereby reducing cellular damage and preventing AKI. Proof-of-concept has been demonstrated in preclinical animal studies, and the company is currently seeking funding to support an Investigational New Drug (IND) filing.
- Brand names
- NephroFortis
- Other names
- NephroFortis
02
Targets
LRP2 (Low-density lipoprotein receptor-related protein 2)
Beyond the preview
Go deeper on NephroFortis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NephroFortis.